Efficacy and Safety of Liraglutide in Patients With an Ileal Pouch-Anal Anastomosis and Chronic High Bowel Frequency: A Placebo-Controlled, Crossover, Proof-of-Concept Study

Am J Gastroenterol. 2024 Sep 1;119(9):1935-1938. doi: 10.14309/ajg.0000000000002801. Epub 2024 Apr 12.

Abstract

Introduction: After colectomy with ileoanal pouch anastomosis (IPAA), many patients develop high bowel frequency (BF) refractory to antimotility agents, despite normal IPAA morphology. Low circulating levels of glucagon-like protein-1 (GLP-1), a modulator of gastroduodenal motility, have been reported after colectomy.

Methods: Double-blind crossover study of 8 IPAA patients with refractory high BF treated with daily administration of the GLP-1 receptor agonist liraglutide or placebo.

Results: Liraglutide, but not placebo, reduced daily BF by more than 35% ( P < 0.03).

Discussion: Larger randomized controlled studies are warranted to delineate the treatment potential of GLP-1 receptor agonists in IPAA patients suffering from noninflammatory high BF.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Colonic Pouches* / adverse effects
  • Cross-Over Studies*
  • Double-Blind Method
  • Female
  • Humans
  • Liraglutide* / therapeutic use
  • Male
  • Middle Aged
  • Postoperative Complications
  • Proctocolectomy, Restorative* / adverse effects
  • Proof of Concept Study
  • Treatment Outcome

Substances

  • Liraglutide